Pharma Focus Asia

QIAGEN Introduces AI-Driven Biomedical Knowledge Base for Accelerating Data-Enabled Drug Discovery

Wednesday, February 28, 2024

QIAGEN has introduced QIAGEN Biomedical KB-AI, a novel knowledge base powered by generative AI, aimed at transforming drug discovery within the pharmaceutical and biotech sectors. This innovative resource caters to data scientists and bioinformaticians seeking extensive knowledge graphs to drive data-centric drug development efforts.

Leveraging a vast dataset sourced from biomedical literature and other scientific references, QIAGEN Biomedical KB-AI discerns and extracts causal connections among genes, diseases, drugs, and other biological elements using AI technology. It boasts over 600 million additional biomedical relationships compared to its predecessor, QIAGEN Biomedical KB-HD. This expansive repository aids data scientists in comprehending disease mechanisms, identifying potential drug targets or biomarkers, and exploring avenues for drug repurposing. Notably, QIAGEN Biomedical KB-AI offers a comprehensive view of biomedical relationships, encompassing edge cases and emerging connections.

While QIAGEN Biomedical KB-HD is renowned for its meticulous manual curation ensuring high quality and accuracy, QIAGEN Biomedical KB-AI stands out with over 25 times more relationships, enabling data scientists to unearth novel insights. Both knowledge bases serve as invaluable resources, providing a blend of high-quality and extensive biomedical relationship data for analysis and validation by professionals in the field.

QIAGEN Digital Insights, remarked, "QIAGEN Biomedical KB-AI marks a significant stride in our commitment to empowering biopharma researchers with comprehensive molecular knowledge bases. By amalgamating AI and human curation methodologies, we furnish researchers with the broadest, most profound, and top-tier knowledge sources."

Key features of QIAGEN Biomedical KB-AI include:

Extensive scale: Curates 640 million biomedical relationships sourced from literature, patents, grants, and various references.
Causal inference: Unveils over 6.4 million gene causal relationships, 1.99 million disease causal relationships, and 1.16 million drug causal relationships.
Structured format: Results are organized in an ontology facilitating swift querying and advanced analytics.
Timely updates: Quarterly updates ensure alignment with the latest research findings and discoveries.
QIAGEN continues to integrate AI advancements across its QIAGEN Digital Insights portfolio, with its most recent enhancement being an AI-driven upgrade to its flagship product, 

QIAGEN Digital Insights, the bioinformatics division of QIAGEN, stands as a leading provider of genomic and clinical knowledge, analysis, and interpretation tools and services for scientists and clinicians. With over 25 years of industry expertise, 90,000 users globally, and more than 100,000 citations in scientific literature, QIAGEN Digital Insights boasts a comprehensive portfolio of expertly curated genomic and clinical knowledge solutions, bioinformatics software, and services aimed at efficient data management, sharing, and actionable insights.

 

Source: globenewswire.com

 

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024